On 9/16/24, Ascendis Pharma AS (NASDAQ: ASND) stock enjoyed a major increase of 17.1%, closing at $139.57. Moreover, this advance was accompanied by exceptionally high trading volume at 520% of normal. The stock has risen 17.1% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
ASND is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Ascendis Pharma AS is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment